Flexibility and inhibitor binding in Cdc25 phosphatases

Proteins: Structure, Function and Bioinformatics

Volumn 78, Issue 14, 2010, Pages 3017-3032

  Arantes, Guilherme Menegon ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Computer simulation; Conformational ensemble; Docking; Intrinsic disorder; Molecular dynamics; Protein tyrosine phosphatases; Receptor flexibility; Transient cavities

Indexed keywords

2,5 DIHYDROXY 3 [7 (2 METHYL BENZYL) 1H INDOL 3 YL][1,4]BENZOQUINONE; 6 CHLORO 7 (2 MORPHOLIN 4 YLETHYLAMINO)QUINOLINE 5,8 DIONE; ENZYME INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BIOINFORMATICS; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; SIMULATION;

CATALYTIC DOMAIN; CDC25 PHOSPHATASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 77957946203     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22826     Document Type: Article

References (79)

1. Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007;7:495-507.
2. Brezak MC, Kasprzyk P, Galcera MO, Lavergne O, Prévost GP. Cdc25 inhibitors as anticancer agents are moving forward. AntiCancer Agents in Med Chem 2008;8:857-862.
3. Lazo JS, Wipf P. Is Cdc25 a druggable target? Anti-Cancer Agents in Med Chem 2008;8:837-842.
4. Bakan A, Lazo JS, Wipf P, Brummond KM, Bahar I. Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening. Curr Med Chem 2008;19:2536-2544.
5. Vintonyak VV, Antonchick AP, Rauh D, Waldmann H. The therapeutic potential of phosphatase inhibitors. Curr Opin Chem Biol 2009;13:272-283.
6. Lavecchia A, Giovanni CD, Novellino E. Cdc25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy. Curr Med Chem 2009;16:1831-1849.
7. Park H, Bahn YJ, Ryu SE. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg Med Chem Lett 2009;19:4330-4334.
8. Rudolph J. Cdc25 phosphatases: structure, specificity, and mechanism. Biochemistry 2007;46:3595-3604.
9. Arantes GM. The catalytic acid in the dephosphorylation of the Cdk2-pTpY/CycA protein complex by Cdc25B phosphatase. J Phys Chem B 2008;112:15244-15247.
10. McCain DF, Catrina IE, Hengge AC, Zhang ZY. The catalytic mechanism of Cdc25A phosphatase. J Biol Chem 2002;277:11190-11200.
11. Arantes GM. Free energy profiles for catalysis by dual-specificity phosphatases. Biochem J 2006;399:343-350.
12. Fauman EB, Cogswell JP, Lovejoy B, Rocque WJ, Holmes W, Montana VG, Piwnica-Worms H, Rink MJ, Saper MA. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 1998;93:617-625.
13. Reynolds RA, Yem AW, Wolfe CL, Deibel MR, Chidester CG, Watenpaugh KD. Crystal structure of the catalytic subunit of Cdc25b required for G(2)/M phase transition of the cell cycle. J Mol Biol 1999;293:559-568.
14. Sohn J, Parks JM, Buhrman G, Brown P, Kristjansdottir K, Safi A, Edelsbrunner H, Yang W, Rudolph J. Experimental validation of the docking orientation of Cdc25 with its Cdk2-CycA protein substrate. Biochemistry 2005;44:16563-16573.
15. Cavanagh J, Fairbrother WJ, Palmer AG, III, Skelton NJ. Protein NMR Spectroscopy: principles and Practice. 2nd edn. New York: Academic Press; 2007.
16. Wilborn M, Free S, Ban A, Rudolph J. The c-terminal tail of the dual-specificity Cdc25B phosphatase mediates modular substrate recognition. Biochemistry 2001;40:14200-14206.
17. Dunker AK, Cortese MS, Romero P, Iakoucheva LM, Uversky VN. The roles of intrinsic disorder in protein interaction networks. FEBS Lett 2005;272:5129-5148.
18. Waf1/CiP1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc Natl Acad Sci USA 1996;93:11504-11509.
19. Wright PE, Dyson HJ. Linking folding and binding. Curr Op Struct Biol 2009;19:31-38.
20. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303:1813-1818.
21. Sotriffer CA, Flader W, Winger RH, Rode BM, Leidl KR, Vargas JM. Automated docking of ligands to antibodies: methods and applications. Methods 2000;20:280-291.
22. Totrov M, Abagyan R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 2008; 18:178-184.
23. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, Emerson A, Fanelli F, Gohlke H, Kuhn LA, Morris GM, Orozco M, Pertinhez TA, Rizzi M, Sotriffer CA. Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 2008;51:6237-6255.
24. Kallblad1 P, Dean PM. Efficient conformational sampling of local side-chain flexibility. J Mol Biol 2003;326:1651-1665.
25. Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in autodock. Proteins: Struct Funct Genet 2002;46:34-40.
26. Erickson JA, Jalaie M, Robertson DH, Lewis RA, Vieth M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem 2004;47:45-55.
27. Knegtel RMA, Kuntz ID, Oshiro CM. Molecular docking to ensembles of protein structures. J Mol Biol 1997;266:424-440.
28. Prasad JC, Goldstone JV, Camacho CJ, Vajda S, Stegeman JJ. Ensemble modeling of substrate binding to cytochromes p450: analysis of catalytic differences between cyp1a orthologs. Biochemistry 2007;46:2640-2654.
29. Burra PV, Zhang Y, Godzik A, Stec B. Global distribution of conformational states derived from redundant models in the pdb points to non-uniqueness of the protein structure. Proc Natl Acad Sci USA 2009;106:10505-10510.
30. Damm KL, Carlson HA. Exploring experimental sources of multiple protein conformations in structure-based drug design. J Am Chem Soc 2007;129:8225-8235.
31. Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of x-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed 2003;42:2718-2736.
32. Wong CF, Kua J, Zhang Y, Straatsma T, McCammon JA. Molecular docking of balanol to dynamics snapshots of protein kinase A. Proteins: Struct Funct Genet 2005;61:850-858.
33. Frembgen-Kesner T, Elcock AH. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 map kinase. J Mol Biol 2006;359:202-214.
34. Ensing B, Vivo MD, Liu Z, Moore P, Klein ML. Metadynamics as a tool for exploring free energy landscapes of chemical reactions. Acc Chem Res 2006;39:73-81.
35. van Aalten D, de Groot B, Berendsen H, Findlay J, Amadei A. A comparison of techniques for calculating protein essential dynamics. J Comput Chem 1997;18:169-181.
36. Zuckerman DM, Lyman E. A second look at canonical sampling of biomolecules using replica exchange simulation. J Chem Theory Comput 2006;3:1200-1202.
37. Nagasima T, Sugita Y, Mitsutake A, Okamoto Y. Generalized-ensemble simulations of spin systems and protein systems. Comp Phys Comm 2002;146:69-76.
38. de Groot B, van Aalten D, Scheek R, Amadei A, Vriend G, Berendsen H. Prediction of protein conformational freedom from distance constraints. Proteins: Struct Funct Genet 1997;29: 240-251.
39. Lange OF, Lakomek NA, Fars C, Schrder GF, Walter KFA, Becker S, Meiler J, Grubmller H, Griesinger C, de Groot BL. Recognition dynamics up to microseconds revealed from an rdc-derived ubiquitin ensemble in solution. Science 2008;320:1471-1475.
40. Shehu A, Kavraki LE, Clementi C. Multiscale characterization of protein conformationl ensembles. Proteins 2009;76:837-851.
41. Bernado P, Blanchard L, Timmins P, Marion D, Ruigrok RWH, Blackledge M. A structural model for unfolded proteins from residual dipolar couplings and small-angle x-ray scattering. Proc Natl Acad Sci USA 2005;102:17002-17007.
42. Das R, Baker D. Macromolecular modeling with rosetta. Annu Rev Biochem 2008;77:363-382.
43. Mamonov AB, Bhatt D, Cashman DJ, Ding Y, Zuckerman DM. General library-based monte carlo technique enables equilibrium sampling of semi-atomistic protein models. J Phys Chem B 2009; 113:10891-10904.
44. Nodet G, Salmon L, Ozenne V, Meier S, Jensen MR, Blackledge M. Quantitative description of backbone conformational sampling of unfolded proteins at amino acid resolution from nmr residual dipolar couplings. J Am Chem Soc 2009;131:17908-17918.
45. McQuarrie DA. Statistical Mechanics. 1st edn. New York: Harper and Row; 1976.
46. Hess B, Kutzner C, van der Spoel D, Lindahl E. Gromacs 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008;4:435-447.
47. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225-11236.
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
49. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, Rydberg E, Man O, Beckmann JS, Silman I, Sussman JL. A simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 2005;21:3435-3438.
50. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004;337:635-645.
51. Peng K, Vucetic S, Radivojac P, Brown CJ, Dunker AK, Obradovic Z. Optimizing intrinsic disorder predictors with protein evolutionary information. J Bioinf Comput Biol 2005;3:35-60.
52. Radivojac P, Iakoucheva LM, Oldfield CJ, Obradovic Z, Uversky VN, Dunker AK. Intrinsic disorder and functional proteomics. Biophys J 2007;92:1439-1456.
53. Liu JS. Monte Carlo strategies in scientific computing. 1st ed. New York: Springer; 2001.
54. Canutescu AA, Shelenkov AA, Dunbrack RL. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 2001;12:2001-2014.
55. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007;28:1145-1152.
56. Daura X, Gademann K, Jaun B, Seebach D, van Gunsteren WF, Mark AE. Peptide folding: when simulation meets experiment. Angew Chem Int Ed 1999;38:236-240.
57. Haykin SS. Neural networks - A comprehensive foundation. 2nd ed. Upper Saddle River, NJ: Prentice-Hall; 1999.
58. Åqvist J, Luzhkov VB, Brandsdal BO. Ligand binding affinities from MD simulations. Acc Chem Res 2002;35:358-365.
59. Pearlman DA, Rao G. Free energy calculations: methods and applications. In: Schleyer PvR, Allinger NL, Clark T, Gasteiger J, Kollman PA, Schaefer IHF, Schreiner PR, editors Encyclopedia of Computational Chemistry, Vol. 2, 1st ed. Chichester: Wiley; 1998. pp. 1036-1061.
60. Hansson T, Marelius J, qvist J. Ligand binding affinity prediction by linear interaction energy methods. J Comput Aid Mol Des 1998;12: 27-35.
61. Benedix A, Becker CM, de Groot BL, Caflisch A, Bckmann RA. Predicting free energy changes using structural ensembles. Nat Methods 2009;6:3-4.
62. Krzeminski M, Fuentes G, Boelens R, Bonvin AM. Minoes: a new approach to select a representative ensemble of structures in nmr studies of (partially) unfolded states. Application to δ 25-PYP. Proteins 2009;74:895-904.
63. Lange OF, Grubmuller H. Generalized correlation for biomolecular dynamics. Proteins: Struct Funct Genet 2006;62:1053-1061.
64. Eftink MR, Anusiem AC, Biltonen RL. Enthalpy-entropy compensation and heat capacity changes for protein-ligand interactions: general thermodynamic models and data for the binding of nucleotides to ribonuclease A. Biochemistry 1983;22:3884-3896.
65. Bakan A, Bahar I. The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding. Proc Natl Acad Sci USA 2009;105:14349-14354.
66. Teague SJ. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2003;2:527-541.
67. Heringa J, Argos P. Strain in protein structures as viewed through nonrotameric side chains: II. Effects upon ligand binding. Proteins: Struct Funct Genet 1999;37:44-55.
68. Gunasekaran K, Nussinov R. How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding. J Mol Biol 2007;365:257-273.
69. Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, Vogt A, Wipf P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem 2001;44:4042-4049.
70. Sohn J, Kiburz B, Li Z, Deng L, Safi A, Pirrung MC, Rudolph J. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. J Med Chem 2003;46:2580-2588.
71. Kallblad P, Mancera RL, Todorov NP. Assessment of multiple binding modes in ligand-protein docking. J Med Chem 2004;47:3334-3337.
72. Shortle D, Simons KT, Baker D. Clustering of low-energy conformations near the native structures of small proteins. Proc Natl Acad Sci USA 1998;95:11158-11162.
73. Krol M, Tournier AL, Bates PA. Flexible relaxation of rigid-body docking solutions. Proteins: Struct Funct Genet 2007;68:159169.
74. Rizzo RC, Tirado-Rives J, Jorgensen WL. Estimation of binding affinities for hept and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. J Med Chem 2001;44:145-154.
75. Khandelwal A, Lukacova V, Kroll DM, Raha S, Comez D, Balaz S. Processing multimode binding situations in simulation-based prediction of ligand-macromolecule affinities. J Phys Chem A 2005; 109:6387-6391.
76. Brisson M, Nguyen T, Wipf P, Joo B, Day BW, Skoko JS, Schreiber EM, Foster C, Bansal P, Lazo JS. Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol 2005;68:1810-1820.
77. Moser CC, Keske JM, Warncke K, Farid RS, Dutton PL. Nature of biological electron transfer. Nature 1992;355:796-802.
78. Lavecchia A, Cosconati S, Limongelli V, Novellino E. Modeling of Cdc25B dual specifity protein phosphatase inhibitors: docking of ligands and enzymatic inhibition mechanism. Chem Med Chem 2006;1:540-550.
79. Kolmodin K, Åqvist J. Prediction of a ligand-induced conformational change in the catalytic core of Cdc25A. FEBS Lett 2000; 465:8-11.